Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507

I. Sekine, Y. Nishiwaki, R. Kakinuma, K. Kubota, F. Hojo, T. Matsumoto, H. Ohmatsu, K. Goto, T. Kodama, K. Eguchi, T. Shinkai, T. Tamura, Y. Ohe, H. Kunitoh, Kimio Yoshimura, N. Saijo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Combinations of cisplatin-irinotecan and cisplatin-etoposide are active and well tolerated in patients with both small-cell lung cancer (SCLC) and nonsmall-cell lung cancer (NSCLC). To define the recommended dose for phase II trials of irinotecan combined with cisplatin and etoposide in chemonaive patients with stage IV disease, 56 patients (11 having SCLC and 45 NSCLC) received cisplatin 25 mg m-2 weekly for 9 weeks, etoposide 60 mg m-2 for 3 days on weeks 1, 3, 5, 7 and 9, and irinotecan 20-100 mg m-2 (levels 1-8) on weeks 2, 4, 6 and 8, together with a prophylactical granulocyte colony-stimulating factor support (50 μg m-2 on days 4-7 on weeks 1, 3, 5, 7 and 9, and on days 2-7 on weeks 2, 4, 6 and 8. Grade 3-4 leukocytopenia, neutropenia and thrombocytopenia were noted in 20 (36%), 28 (50%) and nine (16%) patients, respectively. Grade 3 diarrhoea, grade 3 cardiac toxicity, and grade 4 transaminase elevation developed in one (1.8%) patient each. Totally, four of 56 patients were removed from the study because of toxicity and recovered, and two other patients died in situations where drug toxicity might contribute to their death. Dose-limiting toxicity was noted in less than one-third of patients at dose levels 1-7, but in all patients at dose level 8. Thus, the recommended dose was determined to be level 7 (irinotecan 90 mg m-2). The response rates for SCLC and NSCLC were 91% (10/11) and 38% (17/45), respectively. The median survival time and 1-year survival rate were 11.9 months and 46% for SCLC and 10.1 months and 40% for NSCLC, respectively. This regimen was considered to be feasible and promising for the treatment of stage IV SCLC and NSCLC.

Original languageEnglish
Pages (from-to)808-813
Number of pages6
JournalBritish Journal of Cancer
Volume88
Issue number6
DOIs
Publication statusPublished - 2003 Mar 24
Externally publishedYes

Fingerprint

irinotecan
Etoposide
Cisplatin
Lung Neoplasms
Drug Therapy
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Leukopenia

Keywords

  • Lung cancer
  • Topoisomerase I inhibitor
  • Topoisomerase II inhibitor
  • Weekly chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sekine, I., Nishiwaki, Y., Kakinuma, R., Kubota, K., Hojo, F., Matsumoto, T., ... Saijo, N. (2003). Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507. British Journal of Cancer, 88(6), 808-813. https://doi.org/10.1038/sj.bjc.6600800

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer : JCOG 9507. / Sekine, I.; Nishiwaki, Y.; Kakinuma, R.; Kubota, K.; Hojo, F.; Matsumoto, T.; Ohmatsu, H.; Goto, K.; Kodama, T.; Eguchi, K.; Shinkai, T.; Tamura, T.; Ohe, Y.; Kunitoh, H.; Yoshimura, Kimio; Saijo, N.

In: British Journal of Cancer, Vol. 88, No. 6, 24.03.2003, p. 808-813.

Research output: Contribution to journalArticle

Sekine, I, Nishiwaki, Y, Kakinuma, R, Kubota, K, Hojo, F, Matsumoto, T, Ohmatsu, H, Goto, K, Kodama, T, Eguchi, K, Shinkai, T, Tamura, T, Ohe, Y, Kunitoh, H, Yoshimura, K & Saijo, N 2003, 'Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507', British Journal of Cancer, vol. 88, no. 6, pp. 808-813. https://doi.org/10.1038/sj.bjc.6600800
Sekine, I. ; Nishiwaki, Y. ; Kakinuma, R. ; Kubota, K. ; Hojo, F. ; Matsumoto, T. ; Ohmatsu, H. ; Goto, K. ; Kodama, T. ; Eguchi, K. ; Shinkai, T. ; Tamura, T. ; Ohe, Y. ; Kunitoh, H. ; Yoshimura, Kimio ; Saijo, N. / Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer : JCOG 9507. In: British Journal of Cancer. 2003 ; Vol. 88, No. 6. pp. 808-813.
@article{c4f4ee1c61f44e16abb54a1a2352963d,
title = "Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507",
abstract = "Combinations of cisplatin-irinotecan and cisplatin-etoposide are active and well tolerated in patients with both small-cell lung cancer (SCLC) and nonsmall-cell lung cancer (NSCLC). To define the recommended dose for phase II trials of irinotecan combined with cisplatin and etoposide in chemonaive patients with stage IV disease, 56 patients (11 having SCLC and 45 NSCLC) received cisplatin 25 mg m-2 weekly for 9 weeks, etoposide 60 mg m-2 for 3 days on weeks 1, 3, 5, 7 and 9, and irinotecan 20-100 mg m-2 (levels 1-8) on weeks 2, 4, 6 and 8, together with a prophylactical granulocyte colony-stimulating factor support (50 μg m-2 on days 4-7 on weeks 1, 3, 5, 7 and 9, and on days 2-7 on weeks 2, 4, 6 and 8. Grade 3-4 leukocytopenia, neutropenia and thrombocytopenia were noted in 20 (36{\%}), 28 (50{\%}) and nine (16{\%}) patients, respectively. Grade 3 diarrhoea, grade 3 cardiac toxicity, and grade 4 transaminase elevation developed in one (1.8{\%}) patient each. Totally, four of 56 patients were removed from the study because of toxicity and recovered, and two other patients died in situations where drug toxicity might contribute to their death. Dose-limiting toxicity was noted in less than one-third of patients at dose levels 1-7, but in all patients at dose level 8. Thus, the recommended dose was determined to be level 7 (irinotecan 90 mg m-2). The response rates for SCLC and NSCLC were 91{\%} (10/11) and 38{\%} (17/45), respectively. The median survival time and 1-year survival rate were 11.9 months and 46{\%} for SCLC and 10.1 months and 40{\%} for NSCLC, respectively. This regimen was considered to be feasible and promising for the treatment of stage IV SCLC and NSCLC.",
keywords = "Lung cancer, Topoisomerase I inhibitor, Topoisomerase II inhibitor, Weekly chemotherapy",
author = "I. Sekine and Y. Nishiwaki and R. Kakinuma and K. Kubota and F. Hojo and T. Matsumoto and H. Ohmatsu and K. Goto and T. Kodama and K. Eguchi and T. Shinkai and T. Tamura and Y. Ohe and H. Kunitoh and Kimio Yoshimura and N. Saijo",
year = "2003",
month = "3",
day = "24",
doi = "10.1038/sj.bjc.6600800",
language = "English",
volume = "88",
pages = "808--813",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer

T2 - JCOG 9507

AU - Sekine, I.

AU - Nishiwaki, Y.

AU - Kakinuma, R.

AU - Kubota, K.

AU - Hojo, F.

AU - Matsumoto, T.

AU - Ohmatsu, H.

AU - Goto, K.

AU - Kodama, T.

AU - Eguchi, K.

AU - Shinkai, T.

AU - Tamura, T.

AU - Ohe, Y.

AU - Kunitoh, H.

AU - Yoshimura, Kimio

AU - Saijo, N.

PY - 2003/3/24

Y1 - 2003/3/24

N2 - Combinations of cisplatin-irinotecan and cisplatin-etoposide are active and well tolerated in patients with both small-cell lung cancer (SCLC) and nonsmall-cell lung cancer (NSCLC). To define the recommended dose for phase II trials of irinotecan combined with cisplatin and etoposide in chemonaive patients with stage IV disease, 56 patients (11 having SCLC and 45 NSCLC) received cisplatin 25 mg m-2 weekly for 9 weeks, etoposide 60 mg m-2 for 3 days on weeks 1, 3, 5, 7 and 9, and irinotecan 20-100 mg m-2 (levels 1-8) on weeks 2, 4, 6 and 8, together with a prophylactical granulocyte colony-stimulating factor support (50 μg m-2 on days 4-7 on weeks 1, 3, 5, 7 and 9, and on days 2-7 on weeks 2, 4, 6 and 8. Grade 3-4 leukocytopenia, neutropenia and thrombocytopenia were noted in 20 (36%), 28 (50%) and nine (16%) patients, respectively. Grade 3 diarrhoea, grade 3 cardiac toxicity, and grade 4 transaminase elevation developed in one (1.8%) patient each. Totally, four of 56 patients were removed from the study because of toxicity and recovered, and two other patients died in situations where drug toxicity might contribute to their death. Dose-limiting toxicity was noted in less than one-third of patients at dose levels 1-7, but in all patients at dose level 8. Thus, the recommended dose was determined to be level 7 (irinotecan 90 mg m-2). The response rates for SCLC and NSCLC were 91% (10/11) and 38% (17/45), respectively. The median survival time and 1-year survival rate were 11.9 months and 46% for SCLC and 10.1 months and 40% for NSCLC, respectively. This regimen was considered to be feasible and promising for the treatment of stage IV SCLC and NSCLC.

AB - Combinations of cisplatin-irinotecan and cisplatin-etoposide are active and well tolerated in patients with both small-cell lung cancer (SCLC) and nonsmall-cell lung cancer (NSCLC). To define the recommended dose for phase II trials of irinotecan combined with cisplatin and etoposide in chemonaive patients with stage IV disease, 56 patients (11 having SCLC and 45 NSCLC) received cisplatin 25 mg m-2 weekly for 9 weeks, etoposide 60 mg m-2 for 3 days on weeks 1, 3, 5, 7 and 9, and irinotecan 20-100 mg m-2 (levels 1-8) on weeks 2, 4, 6 and 8, together with a prophylactical granulocyte colony-stimulating factor support (50 μg m-2 on days 4-7 on weeks 1, 3, 5, 7 and 9, and on days 2-7 on weeks 2, 4, 6 and 8. Grade 3-4 leukocytopenia, neutropenia and thrombocytopenia were noted in 20 (36%), 28 (50%) and nine (16%) patients, respectively. Grade 3 diarrhoea, grade 3 cardiac toxicity, and grade 4 transaminase elevation developed in one (1.8%) patient each. Totally, four of 56 patients were removed from the study because of toxicity and recovered, and two other patients died in situations where drug toxicity might contribute to their death. Dose-limiting toxicity was noted in less than one-third of patients at dose levels 1-7, but in all patients at dose level 8. Thus, the recommended dose was determined to be level 7 (irinotecan 90 mg m-2). The response rates for SCLC and NSCLC were 91% (10/11) and 38% (17/45), respectively. The median survival time and 1-year survival rate were 11.9 months and 46% for SCLC and 10.1 months and 40% for NSCLC, respectively. This regimen was considered to be feasible and promising for the treatment of stage IV SCLC and NSCLC.

KW - Lung cancer

KW - Topoisomerase I inhibitor

KW - Topoisomerase II inhibitor

KW - Weekly chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0242668425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242668425&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6600800

DO - 10.1038/sj.bjc.6600800

M3 - Article

C2 - 12644814

AN - SCOPUS:0242668425

VL - 88

SP - 808

EP - 813

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -